Abcam, ab220535, Recombinant cynomolgus monkey LDL Receptor protein (Active)

Size: 100µg
Recombinant cynomolgus monkey LDL Receptor protein (Active) is a Human Fragment protein, in the 22 to 788 aa range, expressed in HEK 293 cells, with >95%, < 1 EU/µg endotoxin level, suitable for SDS-PAGE, FuncS.
Key facts
Purity:>95% SDS-PAGE,
Endotoxin level:< 1 EU/µg,
Expression system:HEK 293 cells,
Tags:His tag C-Terminus,
Applications:SDS-PAGE, FuncSSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Biologically active:Yes,
Biological activity:Measured by its binding ability in a functional ELISA. Immobilized ab220535 at 2 μg/ml (100 μl/well) can bind Biotinylated Human PCSK9, His Tag with a linear range of 0.007-0.256 μg/ml.Immobilized Cynomolgus PCSK9, His Tag at 10 μg/ml (100 μl/well) can bind ab220535 with a linear range of 0.04-0.256 μg/ml.,
Accession:P01130,
Animal free:No,
Carrier free:No,
Species:Human,
Reconstitution:Reconstitute at 200 µg/mL in water,
Storage buffer:pH: 7.4Constituents: PBS, 5% Trehalose

Properties and Storage Information:
Shipped at conditions-Blue Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C, Storage information-Avoid freeze / thaw cycle

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
The LDL Receptor also called LDLR is a protein that plays an important role in the uptake and clearance of low-density lipoproteins (LDL) from the bloodstream. LDLR binds LDL particles facilitating their internalization through receptor-mediated endocytosis. This receptor is expressed mainly in the liver adrenal glands and other tissues involved in cholesterol metabolism. It has an approximate molecular weight of 160 kDa. Researchers often study LDLR using techniques like Western blotting to understand its presence and function.
Biological function summary
The LDL receptor interacts with LDL particles to regulate cholesterol levels in the body. It is part of a cell surface complex that recognizes and binds to apolipoprotein B-100 or apolipoprotein E present on LDL. This interaction initiates internalization of LDL leading to its degradation in lysosomes where cholesterol can be released and used by the cell. Mutations in the gene encoding LDLR can lead to inefficient cholesterol uptake influencing various metabolic processes.
Pathways
LDL receptor activities are integral to lipid metabolism and cholesterol homeostasis. Two important biological pathways that involve LDLR include the cholesterol biosynthesis pathway and the lipoprotein clearance pathway. Within these pathways LDLR collaborates closely with proteins like PCSK9 which modulates its expression and degradation and HMG-CoA reductase an important enzyme in cholesterol synthesis to balance cholesterol levels in the body.
Defects in the LDL receptor are strongly associated with familial hypercholesterolemia and atherosclerosis. These conditions arise from impaired clearance of LDL leading to elevated cholesterol levels which pose risks for cardiovascular diseases. LDLR dysfunctions are linked with the Protein PCSK9 whose gain-of-function mutations can exacerbate hypercholesterolemia by promoting degradation of LDLR while statins aim to increase LDLR expression to lower LDL cholesterol levels.